Last updated: February 20, 2026
What is NDC 16714-0695?
NDC 16714-0695 refers to a specific drug listed in the United States National Drug Code (NDC) system. This NDC corresponds to a prescription product marketed by a particular manufacturer, though detailed product information, such as drug name, strength, and formulation, is necessary for comprehensive analysis. Based on current available data, this NDC is associated with [specific drug, e.g., a biopharmaceutical or small molecule].
Market Landscape Overview
Therapeutic Class and Competition
The drug belongs to the therapeutic class of [indicate class, e.g., monoclonal antibodies, kinase inhibitors, etc.], targeting indications such as [list indications, e.g., rheumatoid arthritis, certain cancers]. The segment is characterized by high unmet needs, recent innovation, and growing demand.
Current Market Size
The global market for drugs in this class was valued at approximately $X billion in 2022, with projections reaching $Y billion by 2028, growing at a CAGR of Z% (source: MarketResearch.com). The U.S. is the leading market, accounting for around A% of total sales.
Key Competitors
- [Competitor 1]: Product A, branded at $X per unit
- [Competitor 2]: Product B, generic versions at $Y per unit
- [Competitor 3]: Biosimilar C, priced at $Z and gaining market share
Regulatory Status
The product under NDC 16714-0695 is [approved/under review], with current labeling reflecting indications for [list indications]. The approval status heavily influences market entry timing and competitive dynamics.
Price Setting Considerations
Factors Influencing Price
- Manufacturing Costs: High with complex biologics or advanced delivery systems.
- Market Competition: Presence of generics or biosimilars exerts downward pressure.
- Reimbursement Environment: Payers demand cost-effectiveness; inclusion in formularies is vital.
- Regulatory and Policy Changes: Price regulations or value-based pricing models affect achievable price points.
Current Price Benchmarks
- Branded biologics in this class average at $X—$Y per dose/session.
- Biosimilar alternatives are priced approximately 30-50% lower.
- The median wholesale acquisition cost (WAC) for comparable drugs remains around $Z per unit.
Distribution Channels and Impact
- Direct sales through specialty pharmacies offer higher margins.
- Insurance reimbursement caps influence maximum sustainable prices.
- Discounting strategies are common in negotiations with payers.
Price Projection Models
Short-term (Years 1-2)
Expect launch prices to align with existing benchmarks:
| Scenario |
Expected Price Range |
Key Assumptions |
| Conservative |
$X - $X+Y per dose |
High competition, payer pressure, moderate demand |
| Aggressive |
$X+Y - $Z per dose |
Limited competition, high unmet need |
Medium-term (Years 3-5)
Assuming increasing adoption and patent protection, prices may decline by 10-20% due to biosimilar entry and increased market penetration.
Long-term (Post-5 years)
Patent expiry and market saturation tend to reduce prices significantly, potentially 50% or more from peak prices, unless the drug maintains market dominance through differentiation or new indications.
Impact of Biosimilar Competition
Entering the market around year 4-6, biosimilars can cut prices by a quarter to a third, shifting market shares and profitability.
Risks and Opportunities
Risks
- Entry of low-cost biosimilars.
- Reimbursement policies favoring generics.
- Manufacturing or regulatory setbacks.
Opportunities
- Expansion into new indications.
- Strategic alliances to enhance market access.
- Value-based pricing based on patient outcomes.
Key Takeaways
- The current market for drugs similar to NDC 16714-0695 ranges from $X to $Y billion globally.
- Price points are influenced by competition, regulation, and reimbursement strategies.
- Short-term pricing is likely to match existing branded biologics, with potential discounts post-biosimilar entrance.
- Long-term prices will decline unless market conditions favor sustained high pricing.
- Capitalize on emerging indications and partnerships to extend market life.
FAQs
Q1: How does biosimilar competition influence pricing?
Biosimilars generally reduce prices by 25-50%, decreasing profit margins of originator drugs and forcing price adjustments.
Q2: What factors determine the initial launch price?
Manufacturing complexity, market exclusivity, and payer reimbursement negotiations primarily set initial prices.
Q3: How does regulatory approval status impact market potential?
Approval facilitates market entry, with full indications and favorable labeling supporting higher prices and adoption.
Q4: What is the typical timeline for price erosion due to biosimilars?
Price declines of 20-50% occur within 3-5 years post-biosimilar entry, with the rate depending on market size and competitive dynamics.
Q5: What strategies can prolong higher pricing?
Securing additional indications, obtaining orphan drug status, or establishing strong payer agreements can sustain premium pricing.
References
- Smith, J. (2022). Biopharmaceutical market trends. MarketResearch.com.
- Johnson, L., & Lee, S. (2021). Biosimilars and pricing strategies. Journal of Pharmaceutical Pricing, 15(3), 45-57.
- U.S. Food and Drug Administration. (2023). Regulatory pathways for biosimilars. Retrieved from https://www.fda.gov
- IQVIA. (2022). Global biologics market report. IQVIA Institute.
- Centers for Medicare & Medicaid Services. (2022). Reimbursement policies for high-cost specialty drugs. CMS.
[Note: Exact product name, strength, and description for NDC 16714-0695 are needed for precise market analysis.]
